13F
中

FENC FENNEC PHARMACEUTICALS INC

2026Q1 · CUSIP 31447P100 · Sector: Healthcare & Biotech

Neutral · No signal
Holders
89
Δ holders QoQ
-7
Breadth percentile
Top 82%
Whale holders
44
Δ whales
-10
Inst. holding value
$100M
New positions
16
Closed positions
23
Price momentum (1Q)
—
Put / Call
0/1

Breadth history (34 quarters)

2018Q1: Δ+4 · h=22 2018Q2: Δ+24 · h=46 2018Q3: Δ+3 · h=49 2018Q4: Δ-1 · h=48 2019Q1: Δ+2 · h=50 2019Q2: Δ-17 · h=33 2019Q3: Δ-5 · h=28 2019Q4: Δ+3 · h=31 2020Q1: Δ-1 · h=30 2020Q2: Δ+26 · h=56 2020Q3: Δ+0 · h=56 2020Q4: Δ-3 · h=53 2021Q1: Δ+0 · h=53 2021Q2: Δ-14 · h=39 2021Q3: Δ-7 · h=32 2021Q4: Δ-2 · h=30 2022Q1: Δ-3 · h=27 2022Q2: Δ+1 · h=28 2022Q3: Δ+3 · h=31 2022Q4: Δ+12 · h=43 2023Q1: Δ+12 · h=55 2023Q2: Δ+2 · h=57 2023Q3: Δ-1 · h=56 2023Q4: Δ+1 · h=57 2024Q1: Δ+8 · h=65 2024Q2: Δ+0 · h=65 2024Q3: Δ-1 · h=64 2024Q4: Δ+1 · h=65 2025Q1: Δ+4 · h=69 2025Q2: Δ+10 · h=79 2025Q3: Δ+6 · h=85 2025Q4: Δ+11 · h=96 2026Q1: Δ-7 · h=89 2018Q1: holders=22 2018Q2: holders=46 2018Q3: holders=49 2018Q4: holders=48 2019Q1: holders=50 2019Q2: holders=33 2019Q3: holders=28 2019Q4: holders=31 2020Q1: holders=30 2020Q2: holders=56 2020Q3: holders=56 2020Q4: holders=53 2021Q1: holders=53 2021Q2: holders=39 2021Q3: holders=32 2021Q4: holders=30 2022Q1: holders=27 2022Q2: holders=28 2022Q3: holders=31 2022Q4: holders=43 2023Q1: holders=55 2023Q2: holders=57 2023Q3: holders=56 2023Q4: holders=57 2024Q1: holders=65 2024Q2: holders=65 2024Q3: holders=64 2024Q4: holders=65 2025Q1: holders=69 2025Q2: holders=79 2025Q3: holders=85 2025Q4: holders=96 2026Q1: holders=89 -26 -13 +0 +13 +26 1960101 18Q119Q120Q121Q122Q123Q124Q125Q126Q1 Δ holders (bar) Holders (line)

Past Lit Events & Aftermath 3 lit events

Period Percentile Next-1Q return Next-2Q return
2023Q1 Top 14% +4.8% +6.2%
2020Q2 Top 13% +46.7% +41.5%
2018Q2 Top 8% — —

Options Sentiment

Put holders
0
QoQ: 0
Call holders
1
QoQ: +1

See methodology →

Fundamentals

PE (TTM)
—
EPS (TTM)
$-0.29
EPS YoY
—
Revenue (TTM)
$0.1B
Revenue YoY
+65.0%
Quarterly Revenue & EPS (4Y)
2023-03-31: $2M 2023-06-30: $3M 2023-09-30: $7M 2023-12-31: $10M 2024-03-31: $25M 2024-06-30: $7M 2024-09-30: $7M 2024-12-31: $8M 2025-03-31: $9M 2025-06-30: $10M 2025-09-30: $12M 2025-12-31: $14M 2026-03-31: $15M 2022-06-30: EPS -0.19 2022-09-30: EPS -0.31 2022-12-31: EPS -0.26 2023-03-31: EPS -0.23 2023-06-30: EPS -0.21 2023-09-30: EPS -0.07 2023-12-31: EPS -0.09 2024-03-31: EPS 0.41 2024-06-30: EPS -0.20 2024-09-30: EPS -0.21 2024-12-31: EPS -0.02 2025-03-31: EPS -0.04 2025-06-30: EPS -0.11 2025-09-30: EPS -0.02 2025-12-31: EPS -0.17 2026-03-31: EPS 0.01 0M 13M 25M $M -0.34 0.05 0.45 20222023202420252026 Revenue EPS

Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable

P/E (TTM) over time
4Y median 176 2024-03-31: PE 1762024-06-30: PE 111.2 100 142 185 20222023202420252026

P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden

As of 2026-03-31 · SEC filings (XBRL)